Navigation Links
Perrigo Announces FDA Final Approval for Miconazole
Date:6/3/2010

ALLEGAN, Mich., June 3 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for over-the-counter (OTC) Miconazole Nitrate Vaginal Cream and Suppository, a generic to Monistat® -1 Combination Pack. Perrigo expects to begin shipping immediately.  

Monistat® -1 has annual retail sales of approximately $90 million dollars.  This OTC product is indicated for the treatment of vaginal yeast infections and for the relief of external itching and irritation they cause. Perrigo was the first to file an ANDA containing a Paragraph IV certification, and the resulting patent litigation filed by Johnson & Johnson was previously dismissed. Perrigo's approval includes 180 days of generic marketing exclusivity.  

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This is another example of Perrigo's commitment to innovation by challenging brand patents and bringing new products to market. These innovations help save OTC healthcare consumers more than an estimated $1 billion annually."      

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Australia, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 27, 2009, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Acquires Rights to Generic Version of HalfLytely® from Novel Laboratories
2. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
3. Perrigo Company Announces Quarterly Dividend
4. Perrigo Acquires Infant Formula Manufacturer PBM Holdings for $808 Million
5. Perrigo Company Announces Quarterly Dividend
6. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
7. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
8. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
9. Perrigo Company To Present at the Sidoti Emerging Growth Conference
10. Perrigo Company Announces Dividend Increase
11. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... , le 27 Avril 2016 ... a progressé de +5% sur le trimestre, soutenu ... de consommables  Croissance de +16% des ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; ... confocale laser, annonce aujourd,hui son chiffre d,affaires pour ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of ... determinant of childhood mortality. This is particularly true in underdeveloped parts of Africa where ... University of New England’s campus in Tangier, Morocco, will examine this global health issue ...
(Date:4/28/2016)... ... April 28, 2016 , ... One way to ignore solid evidence is to ... But we toss the baby out with the bathwater when we ignore all studies ... higher-quality studies and otherwise making better use of education policy research. , “When readers ...
(Date:4/28/2016)... Calif. (PRWEB) , ... April 28, 2016 , ... ... manufacturer specializing in the development of miniature microphones and headsets announced today that ... headset design method of integrating in-earphones into a structure. This innovative design creates ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... it will demonstrate its leading secure mobility workstation suite, SentinelSecure™, at MobileIron’s 6th ... Hilton Union Square, this will be MobileIron’s 6th Mobile First Conference and will ...
(Date:4/28/2016)... North Hollywood, CA (PRWEB) , ... April 28, 2016 , ... ... Getting emergency dental care as soon as possible is essential when it comes to ... and may make the difference between saving and losing a tooth. Toothaches, knocked-out teeth, ...
Breaking Medicine News(10 mins):